- Home
- EDTK vs MBRX Comparison
EDTK vs MBRX Comparison
Compare EDTK & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- MBRX
- Stock Information
- Founded
- EDTK 2013
- MBRX 2015
- Country
- EDTK China
- MBRX United States
- Employees
- EDTK N/A
- MBRX N/A
- Industry
- EDTK Other Consumer Services
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- MBRX Health Care
- Exchange
- EDTK Nasdaq
- MBRX Nasdaq
- Market Cap
- EDTK 16.4M
- MBRX 17.1M
- IPO Year
- EDTK 2020
- MBRX 2016
- Fundamental
- Price
- EDTK $1.14
- MBRX $0.36
- Analyst Decision
- EDTK
- MBRX Strong Buy
- Analyst Count
- EDTK 0
- MBRX 4
- Target Price
- EDTK N/A
- MBRX $5.00
- AVG Volume (30 Days)
- EDTK 8.7K
- MBRX 4.7M
- Earning Date
- EDTK 08-08-2025
- MBRX 11-07-2025
- Dividend Yield
- EDTK N/A
- MBRX N/A
- EPS Growth
- EDTK N/A
- MBRX N/A
- EPS
- EDTK N/A
- MBRX N/A
- Revenue
- EDTK $893,690.00
- MBRX N/A
- Revenue This Year
- EDTK N/A
- MBRX N/A
- Revenue Next Year
- EDTK N/A
- MBRX N/A
- P/E Ratio
- EDTK N/A
- MBRX N/A
- Revenue Growth
- EDTK N/A
- MBRX N/A
- 52 Week Low
- EDTK $0.80
- MBRX $0.25
- 52 Week High
- EDTK $1.20
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- EDTK 59.33
- MBRX 33.84
- Support Level
- EDTK $1.04
- MBRX $0.36
- Resistance Level
- EDTK $1.16
- MBRX $0.42
- Average True Range (ATR)
- EDTK 0.06
- MBRX 0.04
- MACD
- EDTK 0.00
- MBRX -0.01
- Stochastic Oscillator
- EDTK 86.15
- MBRX 6.15
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.